The A. have retrospectively evaluated long-term efficacy and tolerability of GVG as add-on therapy on 220 drug-resistant epileptic pts. After a follow-up ranging from 1 to 6 years, 38% are resulted responders, of which 9% are seizure-free and an additional 15% have achieved a greater than 75% reduction in seizure frequency (good-responders). This group of good- responders pts. is not significantly different from the remaining pts. regarding sex, age, age at onset of seizures, type and frequency of seizures, etiology of epileptic syndrome, number and type of associated AEDs. The only suggestive features are a shorter duration of illness in the good-responders group and the already known effectiveness of GVG in Tuberous Sclerosis. Thus the outcome of GVG treatment is still unpredictable and its efficacy should be verified for each patient.
|Translated title of the contribution||Vigabatrin in add-on therapy in drug-resistant epilepsies. Seven years' experience: Retrospective study on 220 patients|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1998|
ASJC Scopus subject areas
- Clinical Neurology